首页> 外文OA文献 >Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study

【2h】

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study

机译：Camrelizumab联合Folfox4方案作为晚期肝细胞癌的一线治疗：多中心IB / II研究的子队列

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Hui Li; Shukui Qin; Ying Liu; Zhendong Chen; Zhenggang Ren; Jianping Xiong; Zhiqiang Meng; Xiao Zhang; Linna Wang; Xiaojing Zhang; Jianjun Zou;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma [J] . Bo Zhang, Ling Qi, Xi Wang, Cancer Communications . 2020,第12期

机译：II期临床试验使用Camrelizumab结合阿凡替尼和化疗作为先进食管鳞状细胞癌的一线治疗
2. Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy [J] . Puyuan Xing, Mengzhao Wang, Jun Zhao, Thoracic cancer. . 2021,第20期

机译：研究方案：手臂，多中心，Camrelizumab Plus Apatinib用于先前用一线免疫疗法治疗
3. A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy [J] . Lin Zhong-Zhe, Chen Bang-Bin, Hung Yi-Ping, The oncologist . 2020,第9期

机译：先进肝细胞癌失败第一线索中肠道单药治疗的多中心II研究
4. Molecular Therapies in Hepatocellular Carcinoma beyond Sorafenib: Lessons from Failed Phase III Trials and Novel Targets [C] . Lipika Goyal, Andrew X. Zhu Gastrointestinal Cancers Symposium . 2014

机译：Sorafenib之外的肝细胞癌中的分子疗法：III期试验失败的课程和新型靶标
5. Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma [D] . YOSHIDA MAIKO, 吉田舞子 2019

机译：质子治疗后血清α甲胎蛋白和维生素K拮抗剂II水平诱导的蛋白的短暂增加不一定表明肝细胞癌的进展
6. Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study [O] . Hui Li, Shukui Qin, Ying Liu, 2021

机译：Camrelizumab联合Folfox4方案作为晚期肝细胞癌的一线治疗：多中心IB / II研究的子队列
7. A phase I/II multicenter study of single-agent foretinib as first-line therapy in patients with advanced hepatocellular carcinoma [O] . Yau, Thomas C. C., Lencioni, Riccardo, Sukeepaisarnjaroen, Wattana, 2017

机译：I / II期单药Foretinib作为晚期肝细胞癌一线治疗的多中心研究

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study

著录项

引文网络

相似文献

相关主题

期刊订阅